NCT07216443 2026-02-23Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeOrca Biosystems, Inc.Phase 2 Recruiting80 enrolled
NCT02158858 2025-10-08A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesConstellation PharmaceuticalsPhase 1/2 Completed336 enrolled
NCT03066648 2025-05-18Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSNovartisPhase 1 Completed241 enrolled
NCT06034275 2024-11-15Study of VIP943 in Subjects With Advanced CD123+ Hematologic MalignanciesVincerx Pharma, Inc.Phase 1 Recruiting36 enrolled
NCT01345019 2022-11-08Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaAmgenPhase 3 Completed1,718 enrolled 22 charts
NCT01667133 2022-06-13A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)TakedaPhase 1/2 Completed35 enrolled 36 charts
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA
NCT01369498 2020-07-01Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisGilead SciencesPhase 2 Completed54 enrolled 16 charts
NCT01511289 2016-02-24Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsIl-Yang Pharm. Co., Ltd.Phase 3 Completed242 enrolled
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts